arrow
J

James L. Januzzi

massachusetts general hospital
H指数:134
被引数:9.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Translating Guidelines into Practice: Implementation of NT-proBNP Testing for Early Heart Failure Detection in Diabetes, a Narrative Review

将指南转化为实践:糖尿病中NT-proBNP检测用于早期心力衰竭检测的实施,一篇叙事性综述

2026-09-080
PRE
Improvement in Heart Failure Health Status and Functional Capacity After Management in a Guideline-Directed Medical Therapy Clinic

在指南指导的药物治疗门诊管理后心力衰竭患者健康状况和功能能力的改善

2026-08-240
PRE
Demographic Enrollment by Region in Heart Failure Trials: Insights from GUIDE-IT and HF-ACTION

按地区划分的心力衰竭试验人口学入组情况:GUIDE-IT和HF-ACTION试验的启示

2026-07-160
OA
MASLD, MASH, and the CKM Spectrum
JACC
IF0
2026-04-210
PRE
Connectome disruptions after hypoxic-ischaemic injury associate with consciousness disorder severity

缺氧缺血性损伤后的脑连接体破坏与意识障碍严重程度相关

2026-04-020
OA
Sex differences in NT-proBNP associations with risk of heart failure subtypes and response to an intensive lifestyle intervention in type 2 diabetes and overweight or obesity: a post-hoc analysis of the Look AHEAD trial

NT-proBNP与心力衰竭亚型风险及对强化生活方式干预的反应在2型糖尿病和超重或肥胖中的性别差异:Look AHEAD试验的事后分析

2025-10-060
PRE
Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay
2025-10-010
OA
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial

Danicamtiv,一种心脏肌球蛋白选择性激动剂,用于扩张型心肌病:一项II期开放标签试验

JACC
IF0
2025-09-290
OAAI
Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity

胰高血糖素样肽-1受体激动剂对心力衰竭结局及心血管死亡的影响:横跨不同心血管-肾脏-代谢合并症的研究

2025-09-220
PRE
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

心力衰竭伴或不伴糖尿病和慢性肾脏病的患者接受心肌梗死后 empa gliflozin 治疗的疗效:来自 EMPACT-MI 的启示

2025-09-140
OAAI